Introduction
============

China has approximately 1 million new cases of tuberculosis per year,[@R1]^--^[@R3] resulting in a substantial burden of premature mortality.[@R2] Several factors are known to increase the risk of tuberculosis-associated mortality, including drug resistance, disease severity, irregular or incomplete treatment, human immunodeficiency virus (HIV) infection, smoking and alcoholism.[@R4] Multidrug-resistant (MDR) tuberculosis poses a major threat to tuberculosis control. A national survey done in 2008 found that 5.7% of people newly diagnosed with tuberculosis, and 25.6% of those who had previously been treated, had MDR-tuberculosis.[@R5] In Shanghai, China, people being treated for tuberculosis had a case-fatality rate (CFR) of 5.5% in 2008,[@R6] and in 2010 another national survey reported a CFR of 5.1%.[@R7] The purpose of the present study was to determine the mortality rate and excess mortality in a cohort of people with tuberculosis who were registered in four districts of Shanghai from 2004 to 2008 and to identify groups in this cohort at high risk of death.

Methods
=======

The study sample consisted of local residents from four districts in Shanghai City: Yangpu, Pudong, Putuo and Songjiang, with a total population of 9.23 million in 2014. The districts were chosen based on geographic location and tuberculosis notifications. Our study population consisted of 5001 local participants who were registered in tuberculosis clinics under the national tuberculosis programme between January 1, 2004 and December 31, 2008. We included both newly diagnosed and previously treated participants.

Beginning in the 1990s, the national tuberculosis programme implemented a mandatory reporting system for people with tuberculosis in Shanghai. Each person with suspected tuberculosis who seeks health care in facilities in Shanghai is referred to a specialized tuberculosis hospital or clinic where chest X-rays, sputum smears and cultures are done to confirm the diagnosis. Three sputum specimens are routinely collected from each person. People with bacteriological confirmation or abnormal chest X-ray results are routinely treated at a tuberculosis reference hospital or clinic. All *M. tuberculosis* isolates were sent to the tuberculosis reference laboratory at the Shanghai Center for Disease Control and Prevention (CDC) or to the Shanghai Pulmonary Hospital for drug susceptibility testing.

The ethics committee of the School of Public Health of Fudan University approved the study. All participants provided written informed consent to allow their information to be stored and used for research. The study was a sub-study conducted within a larger underlying study.

Definitions
-----------

An isolate was considered as MDR-tuberculosis if it was resistant to both isoniazid and rifampin. Cause of death was based on information in the death certificate and classified according to the *International Statistical Classification of Diseases and Related Health Problems, 10th Revision* (ICD-10).[@R8] Deaths among people with both HIV and tuberculosis are classified as deaths from HIV in ICD-10. Due to a low percentage of HIV-positive people in the study population (0.28--3.30%),[@R9]^,^[@R10] all participants were assumed to be HIV-negative. The case-fatality rate is defined as the risk of death from tuberculosis among people diagnosed with active tuberculosis.[@R11]

Mortality was measured as: (i) the standardized mortality ratio (SMR; see [Box 1](#B1){ref-type="boxed-text"}); and (ii) the case-fatality rate at 1, 5 and 10 years from the start of treatment. The case-fatality rate was estimated as the number of deaths divided by the total number of people with active tuberculosis.

###### Estimating tuberculosis mortality

In 2002, the World Health Organization (WHO) defined any death of a tuberculosis patient during treatment as attributable to tuberculosis, irrespective of the final cause of death.[@R12] As a result, several recent studies used all-cause mortality as a surrogate marker of mortality attributable to tuberculosis.[@R13]

Since 2013, WHO Global Tuberculosis Reports have defined mortality from tuberculosis as any death caused by tuberculosis in HIV-negative individuals.[@R2] When reported as a rate, tuberculosis mortality has typically been expressed as a person-time mortality rate or more commonly as a case-fatality rate (the risk of death from tuberculosis among individuals with active tuberculosis) within a specific time period. However, the case-fatality rates reported for tuberculosis, which range from 12% to 44%, cannot be compared among studies because they were determined as cumulative mortality using different follow-up durations.[@R4]^,^[@R14] In addition, the tuberculosis mortality rate is affected by the baseline mortality rate of the study population.[@R13]^,^[@R15]

A better, though indirect, measure of tuberculosis mortality is the standardized mortality ratio (SMR). The SMR is defined as the observed mortality in people with tuberculosis relative to the expected mortality based on the age-specific mortality rates in a standard population. We used the national population of China in 2013 as our standard population.[@R16]

Baseline survey
---------------

Inclusion criteria were as follows: registered in a tuberculosis clinic under the national tuberculosis programme between January 1, 2004 and December 31, 2008; having household registration or continuous residence at the study site for at least 6 months in the previous year; and provision of written informed consent by the participants or their relatives. Baseline data were collected at the most recent diagnosis of tuberculosis (between 2002 and 2008) and included name, age, sex, residential address, category of treatment and date of registration from the national tuberculosis programme register. Comorbidities, behavioural risk factors (such as smoking) and other data were extracted from paper copies of medical records.

Follow-up
---------

From March to May 2014, health workers visited the households of all participants at least once and interviewed participants or their close relatives who lived in the same household. Deaths were reported by household members and mortality data, including date of death, were collected from death certificates. For quality control, 10% of subjects were re-interviewed; trained public health workers checked data by telephone or in direct visits. Participants were followed up for a range of 1886 to 5205 days (5.17 to 10.67 years), starting from registration to the last follow-up in 2014 or until the date of death.

Regression analysis
-------------------

Univariate and multivariate Cox regression models were used to identify significant co-morbidities during treatment for tuberculosis that were associated with all-cause mortality in SPSS statistical software version 16.0 (SPSS Inc., Chicago, United States of America). Hazard ratios (HR), 95% confidence intervals (CI), and *P*-values were calculated to assess the significance of associations.

Results
=======

A total of 5001 participants met our inclusion criteria ([Table 1](#T1){ref-type="table"}). Of these, 432 were excluded from analysis because they were misdiagnosed, declined to participate in the follow-up, relocated to a district without a tuberculosis register or failed to provide a new address. Of 4569 participants with successful follow-up (91.4%), 3396 were men (74.3%) and 1173 were women (25.7%; [Table 1](#T1){ref-type="table"}). Among the participants, 3601 (78.8%) survived the entire follow-up period from the start of treatment and 968 (21.2%) died. Men were more likely than women to have lung cavitation (29.4% versus 20.3%; *P* \< 0.001), two or more comorbidities (3.0% versus 1.5%, *P* = 0.008) and be smear-positive (48.0% versus 39.1%, *P* \< 0.001), but were less likely to have received previous treatment (10.9% versus 35.5%, *P* \< 0.001).

###### Mortality in tuberculosis patients, Shanghai, China, 2004--2014

  Group                      No.    Person-years follow-up   Observed deaths   Mortality rate per 1 000 person-years   Expected deaths^a^   SMR^b^ (95% CI)^c^
  -------------------------- ------ ------------------------ ----------------- --------------------------------------- -------------------- --------------------
  **All**                    4569   29 744                   968               32.5                                    282.7                5.2 (4.8--5.6)
  **Age group, years**                                                                                                                      
  0--19                      46     301                      0                 0.0                                     0.6                  0.0 (0.0--2.0)
  20--39                     1007   7471                     15                2.0                                     5.0                  0.3 (0.2--0.5)
  40--59                     1771   12 500                   175               14.0                                    58.6                 2.3 (1.9--2.65)
  60--79                     1212   7280                     411               56.5                                    285.8                9.1 (8.2--10.0)
  ≥  80                      525    2101                     363               172.8                                   401.4                27.9 (25.1--30.9)
  Unknown                    8      46                       4                 87.9                                    0.5                  14.2 (3.9--36.3)
  **Sex**                                                                                                                                   
  Male                       3396   21 628                   819               37.9                                    236.9                6.1 (5.7--6.5)
  Female                     1173   8116                     149               18.4                                    62.9                 3.0 (2.5--3.5)
  **Diagnosis**                                                                                                                             
  Secondary pulmonary        4108   26 698                   882               33.0                                    254.7                5.3 (5.0--5.7)
  Primary pulmonary          50     332                      3                 9.0                                     3.1                  1.5 (0.3--4.3)
  Disseminated pulmonary     15     70                       8                 114.8                                   0.9                  18.5 (8.0--36.5)
  Extra-pulmonary            367    2475                     71                28.7                                    22.8                 4.6 (3.6--5.8)
  Other                      29     169                      4                 23.6                                    1.8                  3.8 (1.0--9.8)
  **Treatment management**                                                                                                                  
  Directly-observed          1152   7702                     227               29.5                                    71.4                 4.8 (4.2--5.4)
  Self-administered          30     261                      4                 15.3                                    1.9                  2.5 (0.7--6.3)
  Hospitalized               1907   11 922                   504               42.3                                    118.2                6.8 (6.2--7.4)
  Family-observed            1250   8491                     197               23.2                                    77.5                 3.7 (3.2--4.3)
  Unknown                    230    1368                     36                26.3                                    14.3                 4.2 (3.0--5.9)
  **Previously treated**                                                                                                                    
  Yes                        785    4953                     202               40.8                                    48.7                 6.6 (5.7--7.6)
  No                         3784   24 791                   706               28.5                                    234.6                4.6 (4.3--4.9)
  **MDR-tuberculosis**                                                                                                                      
  Yes                        41     199                      17                85.5                                    2.5                  13.8 (8.0--22.1)
  No                         1449   9671                     354               36.6                                    89.8                 5.9 (5.3--6.6)
  Unknown                    3079   19 874                   597               30.0                                    190.9                4.8 (4.5--5.2)
  **Sputum smear test**                                                                                                                     
  Yes                        2341   12 602                   334               26.5                                    145.1                4.3 (3.8--4.8)
  No                         2089   16 189                   616               38.0                                    129.5                6.1 (5.7--6.6)
  Unknown                    139    952                      18                18.9                                    8.6                  3.0 (1.8--4.8)
  **Cavitation**                                                                                                                            
  Yes                        1235   7892                     257               32.6                                    203.2                5.3 (4.6--5.9)
  No                         3277   21 526                   691               32.1                                    76.6                 5.2 (4.8--5.6)
  Unknown                    57     326                      20                61.4                                    3.5                  9.9 (6.0--15.3)
  **Comorbidity**                                                                                                                           
  Diabetes                   473    2864                     129               45.0                                    29.3                 7.3 (6.1--8.6)
  COPD                       22     100                      14                140.0                                   1.4                  22.6 (12.3--37.9)
  Hypertension               67     385                      28                72.8                                    4.2                  11.7 (7.8--17.0)
  Chronic bronchitis         87     418                      46                110.0                                   5.4                  17.7 (13.0--23.7)
  Cancer                     36     134                      25                186.8                                   2.2                  30.1 (19.5--44.5)

CI: confidence interval; COPD: chronic-obstructive pulmonary disease; MDR: multidrug-resistant; SMR: standardized mortality ratio.

^a^ Calculated by multiplying the number of people with tuberculosis and age specific mortality rates of general population.[@R16]

^b^ Observed divided by expected mortality.

^c^ Calculated assuming a Poisson distribution.

The overall SMR was 5.2 (95% CI: 4.8--5.6); the SMR increased with age in our cohort. Among participants who were 20--39 years-old, the SMR was 0.3 (i.e. lower than the general population), but the SMR increased to 27.9 for participants older than 79 years. Men had a higher SMR than women (6.1 versus 3.0). Participants with disseminated pulmonary disease had a higher SMR (18.5) than those with primary pulmonary disease (1.5) and secondary pulmonary disease (5.3). Previously treated participants had a higher SMR than participants who were undergoing their first treatment for tuberculosis (6.6 versus 4.6). Participants with comorbidities also had high SMRs, especially those with chronic obstructive pulmonary disease (COPD) (22.6) and cancer (30.1).

The 1, 5 and 10 year case-fatality rates were 7.48%, 17.20%, and 21.23%, respectively ([Table 2](#T2){ref-type="table"}). Participants with disseminated pulmonary disease had the highest 1 year case-fatality rate (40.00%), whereas those with cancer had the highest 5 year case-fatality rate (61.11%). The 5 year case-fatality rate was also high for participants older than 79 years (58.89%), with COPD (45.45%), chronic bronchitis (44.83%) or MDR-tuberculosis (39.02%). At the 10 year follow up, the case-fatality rate was highest for participants with cancer (69.44%) or COPD (63.64%) and was also high for those aged 80 years and older (69.02%).

###### Cumulative case-fatality rates in tuberculosis patients, Shanghai, China, 2004--2014

  Subgroup                  No.    Cumulative case-fatality rate, (%)           
  ------------------------- ------ ------------------------------------ ------- -------
  **All**                   4569   7.48                                 17.20   21.23
  **Age group, years**                                                          
  0--19                     46     0.00                                 0.00    0.00
  20--39                    1007   0.40                                 1.09    1.39
  40--59                    1771   3.12                                 8.56    9.59
  60--79                    1212   10.96                                25.75   33.89
  ≥ 80                      525    28.49                                58.89   69.02
  Unknown                   8      12.50                                50.00   50.00
  **Sex**                                                                       
  Male                      3396   8.73                                 19.73   23.96
  Female                    1173   3.93                                 10.00   12.48
  **Diagnosis**                                                                 
  Secondary pulmonary       4108   7.45                                 17.60   21.28
  Primary pulmonary         50     4.00                                 6.00    6.00
  Disseminated pulmonary    15     40.00                                46.67   53.33
  Extra-pulmonary           367    6.81                                 12.81   19.35
  Other                     29     6.90                                 13.79   13.79
  **Clinical management**                                                       
  Directly-observed         1152   5.47                                 15.36   19.44
  Self-administered         30     0.00                                 6.67    13.33
  Hospitalized              1907   11.12                                21.97   26.17
  Family-observed           1250   4.32                                 12.24   15.44
  Unknown                   230    5.22                                 14.35   15.65
  **Previously treated**                                                        
  Yes                       785    8.54                                 20.25   25.48
  No                        3784   7.24                                 16.52   19.98
  **MDR-tuberculosis**                                                          
  Yes                       41     12.20                                39.02   41.46
  No                        1449   6.69                                 18.91   24.15
  Unknown                   3079   7.76                                 16.04   19.13
  **Sputum smear test**                                                         
  Yes                       2341   9.95                                 21.87   26.01
  No                        2089   4.93                                 12.40   15.75
  Unknown                   139    3.60                                 9.35    12.95
  **Cavitation**                                                                
  Yes                       1235   20.16                                44.78   55.47
  No                        3277   2.59                                 6.53    7.66
  Unknown                   57     12.28                                29.82   35.09
  **Comorbidity**                                                               
  Diabetes                  473    9.51                                 21.99   26.85
  COPD                      22     18.18                                45.45   63.64
  Hypertension              67     8.96                                 29.85   41.79
  Chronic bronchitis        87     25.29                                44.83   52.87
  Cancer                    36     36.11                                61.11   69.44

COPD: chronic-obstructive pulmonary disease; MDR: multidrug-resistant.

[Table 3](#T3){ref-type="table"} shows the hazard ratios (HR) for deaths from all causes and from tuberculosis, with and without adjustment for age and sex. The adjusted HRs for deaths from all causes were 1.50 (95% CI: 0.91--2.48) for participants with MDR-tuberculosis, 1.55 (95% CI: 1.35--1.78) for smear-positive participants, and 1.26 (95% CI: 1.08--1.49) for previously treated participants. The adjusted HRs for deaths from tuberculosis were 1.77 (95% CI: 0.62--5.06) in participants with MDR-tuberculosis, 3.16 (95% CI: 2.06--4.87) for smear-positive participants and 1.88 (95% CI: 1.24--2.86) for previously treated participants. We also calculated the adjusted HRs for participants with diabetes (0.97; 95% CI: 0.80--1.17), COPD (1.47; 95% CI: 0.86--2.50), hypertension (1.43; 95% CI: 0.84--2.46), chronic bronchitis (1.42; 95% CI: 1.05--1.94) and cancer (1.93; 95% CI: 1.29--2.90).

###### Crude and adjusted hazard ratios for mortality in tuberculosis patients, Shanghai, China, 2004--2014

  Subgroup                  HR (mortality from tuberculosis)                        HR (mortality from all causes)          
  ------------------------- ---------------------------------- -------------------- -------------------------------- ------ -------------------
  **Diagnosis**                                                                                                             
  Secondary pulmonary       1.00                               1.00                                                  1.00   1.00
  Primary pulmonary         0.66                               1.42 (0.19--10.39)                                    0.28   0.68 (0.22--2.13)
  Disseminated pulmonary    2.31                               1.86 (0.26--13.51)                                    3.38   2.10 (1.04--4.24)
  Extra-pulmonary           0.72                               0.68 (0.33--1.40)                                     0.84   0.81 (0.63--1.05)
  Other                     1.58                               1.46 (0.20--10.65)                                    0.69   0.85 (0.32--2.29)
  **Clinical management**                                                                                                   
  Directly-observed         1.00                               1.00                                                  1.00   1.00
  Self-administered         --                                 --                                                    0.57   1.22 (0.45--3.34)
  Hospital                  1.80                               2.09 (1.18--3.73)                                     1.43   1.39 (1.14--1.69)
  Family-observed           0.64                               0.97 (0.47--1.98)                                     0.79   0.99 (0.79--1.25)
  Unknown                   1.70                               1.76 (0.64--4.87)                                     0.87   0.88 (0.57--1.35)
  **Previously treated**                                                                                                    
  Yes                       1.67                               1.88 (1.24--2.86)                                     1.31   1.26 (1.08--1.49)
  No                        1.00                               1.00                                                  1.00   1.00
  **MDR-tuberculosis**                                                                                                      
  Yes                       2.79                               1.77 (0.62--5.06)                                     2.12   1.50 (0.91--2.48)
  No                        1.00                               1.00                                                  1.00   1.00
  Unknown                   0.65                               0.72 (0.48--1.08)                                     0.81   0.95 (0.82--1.11)
  **Sputum smear test**                                                                                                     
  Yes                       4.33                               3.16 (2.06--4.87)                                     2.31   1.55 (1.35--1.78)
  No                        1.00                               1.00                                                  1.00   1.00
  Unknown                   1.21                               1.34 (0.32--5.67)                                     0.93   0.97 (0.60--1.56)
  **Cavitation**                                                                                                            
  Yes                       1.28                               1.32 (0.91--1.93)                                     0.99   1.04 (0.90--1.20)
  No                        1.00                               1.00                                                  1.00   1.00
  Unknown                   2.74                               2.69 (0.97--7.45)                                     1.84   1.59 (1.02--2.49)
  **Comorbidity**                                                                                                           
  Diabetes                  1.09                               0.85 (0.49--1.46)                                     1.40   0.97 (0.80--1.17)
  COPD                      1.58                               0.88 (0.12--6.37)                                     4.05   1.47 (0.86--2.50)
  Hypertension              0.50                               0.28 (0.04--2.03)                                     5.29   1.43 (0.84--2.46)
  Chronic bronchitis        3.00                               2.03 (0.91--4.54)                                     3.33   1.42 (1.05--1.94)
  Cancer                    1.96                               1.26 (0.31--5.16)                                     5.10   1.93 (1.29--2.90)

CI: confidence interval; COPD: chronic obstructive pulmonary disease; HR: hazard ratios; MDR: multidrug resistant.

^a^ Based on Cox regression models, adjusted for age and sex.

The cumulative survival curves ([Fig. 1](#F1){ref-type="fig"}) show that the highest risk of death was in the first year, especially during the 2-month intensive treatment phase. After the treatment period, survival improved, especially when considering deaths from tuberculosis only.

![Survival curves for study participants, Shanghai, China, 2004--2014](BLT.15.154161-F1){#F1}

Discussion
==========

The risk of death in the study population was five times that in the general population of China (SMR 5.2). This is lower than previously reported for people with tuberculosis in India (6.1),[@R17] the Netherlands (8.3),[@R18] and Ethiopia (10.0),[@R19] at least in part because there is less co-infection with HIV in China.[@R20] Men had higher mortality rates than women, which may be because of sex differences in clinical characteristics (smear results, cavitation, prevalence of comorbidities and MDR-tuberculosis),[@R21] a higher likelihood of noncompliance with treatment, or the presence of additional risk factors such as smoking.[@R6]^,^[@R17]^,^[@R19]^,^[@R22] Participants with disseminated pulmonary disease, smear-positive disease or MDR-tuberculosis had higher SMRs than those without these characteristics. This is as expected, given that all of these characteristics are related to disease severity.

Among our participants, 25% were undergoing directly observed treatment, short-course (DOTS) facilitated by health-care workers. Contrary to the general expectation that DOTS will substantially increase the effectiveness of treatment for tuberculosis,[@R23]^,^[@R24] we found that participants receiving DOTS facilitated by health-care workers had a higher cumulative case-fatality rate than those under self-administered and family-observed management. This may be because people who were willing to remain under DOTS were in poorer health than those under self-administered and family-observed management. Consistent with our findings for Shanghai, studies in Ethiopia,[@R25] India[@R26] and the United Republic of Tanzania[@R27] also reported good treatment outcomes following self-administered tuberculosis treatment. However, contrary results have been obtained in other settings. For example, a study of health-community workers found that DOTS was more beneficial than family-observed management,[@R28] and a randomized trial in Nepal indicated that family-observed management produced similar outcomes as health-community worker facilitated DOTS.[@R29] Hospitalized people with tuberculosis in China typically have severe disease, which is consistent with this group having the highest cumulative case-fatality rate in our cohort.[@R30]

Mortality was highest in the first year, and then declined substantially with time in almost all of the analysed subgroups. During the 10 year follow-up, about one third of the deaths occurred in the first year, and 80% of the deaths occurred within five years of diagnosis. Tuberculosis-related mortality continued to occur even after the completion of treatment. This emphasizes that the definition of tuberculosis mortality should not be restricted to the treatment period alone, because this may lead to an underestimation of tuberculosis-related mortality.

Previous studies have identified several co-morbidities that are risk factors for all-cause mortality during tuberculosis treatment, including renal failure, respiratory disease, cardiovascular disease, cancer, COPD and diabetes.[@R31]^--^[@R33] Our analysis identified several such comorbidities. In univariate analyses, people with tuberculosis with diabetes, COPD, chronic bronchitis, hypertension and cancer also had increased mortality. However, after adjusting for age and sex, only chronic bronchitis and cancer were significantly associated with death from all causes. The impact of chronic bronchitis on all-cause mortality is consistent with our previous report.[@R15] It is possible that damage from chronic bronchitis may exacerbate some of the symptoms of tuberculosis, as both conditions are associated with chronic airflow obstruction and other respiratory symptoms.[@R34]

Our study has several limitations. First, we did not ascertain the HIV status of participants because HIV testing is not compulsory for people with tuberculosis in China. However, previous screening studies reported that the HIV prevalence among people with tuberculosis in China was low.[@R9]^,^[@R10] Second, we determined the cause of death using the death certificate database. In Shanghai, a death registration system was established based on ICD-10 for defining the causes of death. Thus, there may have been misclassification of tuberculosis deaths, although misclassification bias would have been reduced by our policy of confirming cause of death during follow-up. Participants who self-administered treatment were possibly marked as being under DOTS in the tuberculosis management system,[@R35] which may have introduced a bias. Loss to follow-up during or after treatment may have led to an overestimation of mortality rates, since recording of deaths from the death registration database is nearly complete. Finally, although geographic characteristics and tuberculosis prevalence were considered in selecting the study districts, the selected districts may not have provided a representative sample of the population of Shanghai.

Conclusion
==========

In this cohort of people with tuberculosis in Shanghai, mortality was higher during treatment, suggesting the importance of improving clinical management and treatment for tuberculosis. Interventions during treatment (i.e. monitoring and managing the side-effects of anti-tuberculosis medication) may reduce the rate of tuberculosis deaths while follow-up can lead to reduced deaths from other causes. Timely detection and management of comorbidities among people with tuberculosis is necessary to prevent deaths during treatment for tuberculosis, as reported by other studies.[@R36] People with tuberculosis and major comorbidities such as chronic bronchitis and lung cancer need careful management. When appropriate, follow-up and assessment coordinated by tuberculosis departments may improve the management of these conditions. Post-treatment mortality could be used as additional evidence of case fatality (obtained through routine reports) to better characterize overall mortality in people with tuberculosis.
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